In this edition of The National Observer, we look at why pharmacy chains are closing — and what it means for areas that'll ...

For CVS, Q2 earnings will be a critical inflection point. A miss could trigger a breakup or further decline, making the stock ...

The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

The California Public Employees’ Retirement System (CalPERS) has a new pharmacy benefits contract with CVS Caremark, the ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Study: Health of children in USA getting worse. A new study says the health of American children has gotten worse across the ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Bil Schmidtknecht blames pharmacy benefit managers for the death of his son. He won’t rest until he holds them accountable.

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?